EQUINOX NEPREMICNINE d.d. (LJSE:EQNX)

Slovenia flag Slovenia · Delayed Price · Currency is EUR
63.00
0.00 (0.00%)
At close: Jul 30, 2025
Market Cap112.51M
Revenue (ttm)9.71M
Net Income (ttm)1.30M
Shares Out1.79M
EPS (ttm)0.73
PE Ratio86.67
Forward PEn/a
Dividend1.83 (2.90%)
Ex-Dividend DateJun 16, 2025
Volume1
Average Volume49
Open63.00
Previous Close63.00
Day's Range63.00 - 63.00
52-Week Range54.00 - 65.50
Beta-0.05
RSI58.99
Earnings DateJul 24, 2025

About Blueprint Medicines

EQUINOX NEPREMICNINE d.d. engages in the rental and operation of real estate properties in Slovenia. Its properties include hotels, offices, and apartments. The company was founded in 2021 and is headquartered in Ljubljana, Slovenia. EQUINOX NEPREMICNINE d.d. operates as a subsidiary of Axorholding d.d. [Read more]

Industry Operators of Nonresidential Buildings
Founded 2021
Country Slovenia
Stock Exchange Ljubljana Stock Exchange
Ticker Symbol EQNX
Full Company Profile

Financial Performance

In 2024, EQUINOX NEPREMICNINE d.d.'s revenue was 8.67 million, an increase of 11.36% compared to the previous year's 7.79 million. Earnings were 1.07 million, an increase of 23.06%.

Financial Statements

News

There is no news available yet.